AbbVie Still Has Room to Run: A Tactical Long on Durable Growth and Yield
AbbVie ($264.56) is trading near its 52-week high while fundamentals and technicals point to further upside. With free cash flow of $18.21B, a 2.6% yield, accelerating growth from Skyrizi and Rinvoq, and bullish momentum signals, a controlled long with a $255 stop and $285 target offers an asymmetric risk-reward over the next 45 trading days.